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Abstract
In this study, we showed the direct interaction between 
Mycobacterium  avium  subsp.  paratuberculosis f i -
bronectin attachment protein (FAP) and toll-like re-
ceptor4 (TLR4) via co-localization and binding by us-
ing confocal microscopy and co-immunoprecipitation 
assays. FAP triggered the expression of pro- and anti- 
inflammatory cytokines in a TLR4-dependent manner. 
In addition, FAP-induced cytokine expression in bone 
marrow-derived dendritic cells (BMDCs) was modu-
lated in part by glycogen synthase kinase-3 (GSK-3). 
FAP-induced expression of CD80, CD86, major histo-
compatibility complex (MHC) class I, and MHC class II 
in TLR4
+/+ BMDCs was not observed in TLR4
-/- BMDCs. 
Furthermore, FAP induced DC-mediated CD8
+ T cell 
proliferation and cytotoxic T lymphocyte (CTL) activ-
ity, and suppressed tumor growth with DC-based tu-
mor vaccination in EG7 thymoma murine model. Taken 
together, these results indicate that the TLR4 agonist, 
FAP, a potential immunoadjuvant for DC-based cancer 
vaccination,  improves  the  DC-based  immune  re-
sponse via the TLR4 signaling pathway.
Keywords: dendritic cells; FAP-A protein, Mycobac-
terium avium; glycogen synthase kinase-3; toll-like re-
ceptor 4
Introduction
Dendritic cells (DCs), which are representative 
antigen-presenting cells (APCs), play a pivotal role 
in the modulation of the immune response to 
various antigens via toll-like receptors (TLRs) 
(Watts  et al., 2010). Immature DCs capture and 
process antigens in the peripheral tissues 
(Banchereau  et al., 2000). After antigen uptake, 
mature DCs migrate to draining lymph nodes, 
wherein they activate naïve T-cells by upregulating 
surface molecules, including CD80, CD86, major 
histocompatibility complex (MHC) class I, and 
MHC class II (Alvarez et al., 2008). In addition, M. avium subsp. paratuberculosis FAP for cancer vaccines    341
Figure 1. FAP interacts with TLR4. (A) Co-localization of FAP and TLR4 
on DCs. DCs were treated with FAP (500 ng/ml) for 30 min, fixed, and 
stained with rabbit anti-FAP and mouse PE-conjugated anti-TLR4 anti-
bodies overnight at 4
oC, and then stained with Alexa568-conjugated an-
ti-rabbit antibody for 1 h at room temperature. Cell morphology and fluo-
rescence intensity were analyzed using the Zeiss LSM510 Meta confocal 
laser scanning microscope. (B) Co-immunoprecipitation of FAP and 
TLR4. DCs were treated with FAP (500 ng/ml) for 30 min. Cells were har-
vested, cell lysates were immunoprecipitated with IgG and anti-FAP, and 
proteins were visualized by immunoblotting with an anti-TLR4 antibody. 
mature DCs can secrete various immunoregulatory 
cytokines such as interleukin (IL)-12, IL-6, and IL-10, 
which are regulators of inflammatory responses, 
and activate innate immune cells (Jensen and Gad, 
2010). Thus, it is well accepted that DC serves as 
a crucial linker between innate and adaptive 
immune response (Liu, 2001). The activation of 
nuclear factor kappa B (NF-κB) and mitogen-activated 
protein kinases (MAPKs), including extracellular 
signal-regulated kinase (ERK), c-jun N-terminal 
kinase (JNK), and p38, via TLRs regulates the 
maturation and differentiation of DCs (Rescigno et 
al., 1998).
    The  recognition  of  microbial  products  such  as 
lipopolysaccharide (LPS) is initiated by TLRs, 
which recruit various signaling molecules, including 
the adaptor molecules myeloid differentiation 
protein 88 (MyD88), tumor necrosis factor 
receptor-associated factor 6 (TRAF6) and MyD88 
adapter-like (MAL), resulting in the activation of 
downstream signaling pathways such as MAPKs 
and NF-κB (Akira et al., 2001). Because TLR 
activation usually polarizes Th1 responses, TLR 
agonists are potent candidates for immune 
adjuvants in tumor therapy (Matijevic and Pavelic, 
2010). Among these mentioned TLR agonists, TLR4 
agonists are more suitable for immunostimulatory 
adjuvants due to the DC-based immune boosting 
potency via TLR4 signaling cascade (Napolitani et 
al., 2005). 
    Glycogen synthase kinase-3 (GSK-3) was first 
identified as a key regulator of the glycogen 
metabolism; it regulates various cellular processes 
such as apoptosis, differentiation, growth, cell 
motility, and embryonic development by modulating 
various substrates (Cohen and Frame, 2001; 
Woodgett, 2001; Jope and Johnson, 2004). Recent 
studies have shown the role of GSK-3 as a regulator 
of immune responses, including activation and 
differentiation of DCs and endotoxemia (Rodionova 
et al., 2007; Noh et al., 2011).
    Fibronectin  (FN)  attachment  proteins  (FAPs) 
belong to a family of FN-binding glycoproteins that 
are expressed by several species of mycobacteria 
(Ratliff  et al., 1993; Schorey et al., 1995, 1996; 
Secott et al., 2001). FAP is crucial for attachment 
and internalization of Mycobacterium bovis BCG 
and  M. avium subsp. avium to tissue of host 
(Middleton  et al., 2000; Zhao et al., 2000). These 
processes were proved to be a FAP-dependent 
process (Kuroda et al., 1993; Schorey et al., 1995). 
M. avium subsp. paratuberculosis also expresses 
a FAP which mediates soluble FN binding (Secott 
et al., 2001). In a previous report, we had shown 
that FAP expressed by M. avium enhances the 
immune response via regulation of DCs (Lee et al., 
2009). However, the detailed mechanism of the 
FAP-regulated immune response is less defined. 
        In this study, we have shown the direct 
interaction between FAP and TLR4 in BMDCs. The 
expression of surface markers, including CD80, 
CD86, MHC class I, and MHC class II, and pro- and 
anti-inflammatory cytokines by FAP is TLR4- 
dependently modulated. In addition, we identified 
that DC-mediated CD8
+ T cell proliferation and 
cytotoxic T lymphocyte activity by FAP is via GSK-3.
Results
FAP interacts with TLR4 in BMDCs
Previously, it was shown that M. avium regulates 
the immune response through modulation of DC 
maturation (Lei and Hostetter, 2007). Furthermore, 
we determined that the M. avium protein FAP is 
quite effective in inducing DC maturation and Th1 
polarization (Lee et al., 2009). However, the precise 
mechanism by which this antigen mediates 
immune stimulation has not been defined. A Th1 342    Exp. Mol. Med. Vol. 44(5), 340-349, 2012
Figure 2. The expression of the pro-inflammatory cytokines (IL-12 and TNF-α) and the anti-inflammatory cytokine IL-10 was enhanced by FAP treatment 
in a TLR4-dependent manner, and GSK-3 is involved in the effect of FAP. (A) TLR4
+/+ and TLR
-/- BMDCs were stimulated with FAP (500 ng/ml). After 24 h, 
the concentrations of IL-12, TNF-α, and IL-10 were measured in the culture supernatants by ELISA. The mean (SEM) values shown represent 3 in-
dependent experiments. *P ＜ 0.05, **P ＜ 0.01, ***P ＜ 0.001 compared with untreated TLR4
+/+ BMDCs. (B) BMDCs were pretreated with or without 
the indicated GSK-3 inhibitor (SB415286) concentration for 30 min and then harvested after 24 h of incubation with FAP (500 ng/ml). The cytokine con-
centrations in culture supernatants were measured by ELISA. The mean ± SEM values shown represent 3 independent experiments. *P ＜ 0.05, **P ＜
0.01, ***P ＜ 0.001 compared with untreated BMDCs.
response is usually triggered by TLR activation in 
dendritic cells. Using confocal microscopy and 
co-immunoprecipitation assays, we found that FAP 
co-localizes and binds with TLR4 in BMDCs 
(Figure 1). These data demonstrates that FAP 
interacts with TLR4. Next, we investigated whether 
FAP plays a role as one of the TLR4 ligands by 
using  TLR4
-/- BMDCs. FAP activated MAPKs, 
including ERK, JNK, and p38, and NF-κB in the 
presence of TLR4, but this phenomenon was not 
observed in cells in which TLR4 was knocked out 
(Supplemental Data Figure S1).
The expression of the pro-inflammatory cytokines 
(IL-12 and TNF-α) and the anti-inflammatory cytokine 
IL-10 was enhanced by FAP treatment in a TLR4- 
dependent manner, and GSK-3 is involved in the 
effect of FAP
Next, we investigated whether stimulation of DCs 
with FAP affects the production of pro- and 
anti-inflammatory cytokine that modulate the 
polarization of Th1 and Th2 cells via TLR4. We 
analyzed the production of the pro-inflammatory 
cytokines IL-12 and TNF-α and that of the anti- 
inflammatory cytokine IL-10 in FAP-treated TLR4
+/+ 
and TLR4
-/- BMDCs using the ELISA method. FAP 
treatment elevated the production of the 
pro-inflammatory cytokines IL-12 and TNF-α as 
well as that of the anti-inflammatory cytokine IL-10, 
but the increase in the production of those 
cytokines by FAP was impaired in the absence of 
TLR4 (Figure 2A). Thus, the FAP-mediated cytokine 
production, which is crucial for the modulation of 
DC functions, was also regulated in a TLR4- 
dependent manner.
    In a recent publication, M. Martin et al. provided 
an evidence that GSK-3 modulates various cytokines, 
including IL-12 and TNF-α, via TLR4 (Martin et al., 
2005). Thus, we examined whether GSK-3 is 
involved in the modulation of the abovementioned 
cytokines in the presence of FAP. Inhibition of 
GSK-3 resulted in the reduction of the IL-12 and 
TNF-α production compared with the FAP-treated 
control, whereas the IL-10 production was 
dramatically enhanced (Figure 2B). This result 
demonstrates that GSK-3 is one of signaling 
pathway involved in the cytokine modulation by 
FAP.M. avium subsp. paratuberculosis FAP for cancer vaccines    343
Figure  3. FAP induces the ex-
pression of MHC class I and II and 
co-stimulatory molecules (CD80 and 
CD 86) in wild type and TLR2
-/-
BMDCs, but the expression of those 
molecules was impaired in TLR4
-/-
BMDCs. On day 6 of culturing, 
BMDCs were pretreated with or with-
out the indicated GSK-3 inhibitor 
(SB415286) concentration for 30 
min and then harvested after 24 h of 
incubation with FAP (500 ng/ml). 
BMDCs were first gated for CD11c
+
cells and analyzed by two-color flow 
cytometry. (A) FAP induces the ex-
pression of co-stimulatory mole-
cules (CD80 and CD86) in wild type 
and  TLR2
-/- BMDCs, but the ex-
pression of these molecules was im-
paired in TLR4
-/- BMDCs. The mean 
fluorescence intensity (MFI) of dou-
ble-positive cells is shown for each 
panel. The mean ± SEM values 
shown represent 3 independent 
experiments. **P ＜ 0.01 compared 
with untreated BMDCs. (B) FAP in-
duces expression of MHC class I 
and II in wild type and TLR2
-/- BMDCs, 
but the expression of these mole-
cules was impaired in TLR4
-/- BMDCs. 
The mean fluorescence intensity 
(MFI) of double-positive cells is 
shown for each panel. The mean ±
SEM values shown represent 3 in-
dependent experiments. *P ＜ 0.05 
compared with untreated BMDCs.
FAP induces the expression of co-stimulatory (CD80 
and CD 86) and MHC class I and II molecules in TLR4
+/+ 
BMDCs, but the expression of those molecules was 
impaired in TLR4
-/- BMDCs
The activation of TLR4, one of the crucial proteins 
in innate and adaptive immune responses, by 
various stimuli leads to the maturation of DCs. 
Thus, we examined the effect of FAP on DC 
maturation by investigating the expression of 
surface markers using flow cytometry. We found 
increased expression of surface markers, including 
CD80, CD86, MHC class I, and MHC class II, in 
FAP-treated TLR4
+/+ BMDCs, but this phenomenon 
was not observed in FAP-treated TLR4
-/- BMDCs 
(Figure 3). However, the expression of the 
abovementioned surface markers was still activated 
by FAP in TLR2
-/- BMDCs (Figure 3). In addition, 
FAP-mediated DC maturation was impaired in 
GSK-3 inhibitor-treated condition. From this result, 
we concluded that DC maturation mediated by 
FAP occurs via the TLR4 rather than the TLR2 
signaling pathway, and FAP-mediated DC 
maturation is partly dependent on GSK-3.344    Exp. Mol. Med. Vol. 44(5), 340-349, 2012
Figure 3. Continued.
FAP-treated DCs induce proliferation and CTL 
activity of CD 8
+ T-cell via GSK-3 activity
To determine whether the FAP-induced maturation 
of DCs affects T-cell activation, we performed a 
mixed lymphocyte reaction (MLR) assay using 
CD8
+ T-cells of OT-1 TCR transgenic mice, which 
express a TCR specific for the MHC class I-restricted 
Ovalbumin (OVA) peptide 257-264 antigen 
(OVA257-264) in DCs (Hogquist et al., 1994). The 
proliferation of CFSE- labeled OVA-specific CD8
+ 
T-cells co-cultured with FAP-treated DCs pulsed 
with OVA257-264 was significantly higher than that of 
T-cells co-cultured with untreated DCs pulsed with 
OVA257-264 (Figure 4A). In addition, the 
FAP-mediated enhanced CD8
+ T-cell proliferation 
was dramatically inhibited by the treatment with the 
GSK-3 inhibitor SB415286 (Figure 4A). Above 
FAP-mediated CD8
+ T-cell proliferation was not 
observed in the absence of TLR4 (Supplemental 
Data Figure S2). These results show that FAP 
functions as an immunostimulator for DC-mediated 
CD8
+ T-cell proliferation via TLR4- GSK-3 signaling 
cascade.
    Next,  we  investigated  whether  FAP-mediated 
CD8
+ T-cell proliferation causes cytotoxic T 
lymphocyte (CTL) responses. OVA-pulsed DCs M. avium subsp. paratuberculosis FAP for cancer vaccines    345
Figure 4. FAP-treated DCs induce proliferation and CTL activity of CD 8
+ T-cells via GSK-3 activity. (A) Immature DCs, OVA-pulsed DCs, OVA-pulsed 
FAP-treated DCs, or OVA-pulsed FAP + GSK-3 inhibitor-treated DCs were cultured with CFSE-labeled splenocytes of OT-1 T-cell receptor transgenic 
mice (1 ×10
6 per well) for 72 h. After 3 days, the cells were harvested and stained with Cy5-labeled anti-CD8 monoclonal Ab and analyzed by flow 
cytometry. Histograms showing CD8
+ T-cell proliferation as assessed by flow cytometry. The mean ± SEM values shown represent 3 independent 
experiments. *P ＜ 0.05, **P ＜ 0.01 compared with immature DCs. (B) In mixed cultures, immature DCs, OVA-pulsed DCs, OVA-pulsed FAP-treated 
DCs, or OVA-pulsed FAP + GSK-3 inhibitor-treated DCs were cultured with splenocytes of OT-1 T-cell receptor transgenic mice (1 ×10
6 per well) for 72 
h and then co-cultured with EL4 (1 ×10
6 cells stained with 10 μM CFSE) or EG7 (1 ×10
6 cells stained with 10 μM CFSE) cells. After 4 hours, mixed 
lymphocyte tumor cultures were analyzed by flow cytometry. The percentage in M1 indicates CFSE-stained EG7 cells and that in M2 indicates lysed cell 
debris of CFSE-stained EG7 cells. The mean ± SEM values shown represent 3 independent experiments. *P ＜ 0.05 compared with immature DCs.
reduced the population of CSFE-stained OVA- 
expressing EG7 tumor cells compared to 
non-pulsed DCs, and OVA-expressing EG7 tumor 
cells were significantly lysed in FAP-treated DCs 
pulsed with OVA257-264 (Figure 4B, upper). Further-
more, this increased CTL activity by FAP was 
inhibited following GSK-3 inhibition (Figure 4B, 
upper). However, FAP-mediated modulation of 
DCs did not affect the CTL responses against 
non-OVA-expressing EL4 tumor cells (Figure 4B, 
bottom). From these data, we concluded that 
FAP-treated DCs pulsed with OVA257-264 potentiates 
the OVA-specific CTL activity via the GSK-3 
signaling pathway.
FAP triggers DC-derived anti-tumor activity in vivo
Among the many TLR agonists, TLR4 agonists 
have a promising potential as immunostimulatory 
adjuvants because TLR4 signaling strongly 
induces DC maturation (Kaisho et al., 2001). In 
addition, it has been well documented that the 
expression of TLR4 on DCs is crucial for the 
anti-tumor effects of DC-based immunotherapy 
(Cisco et al., 2004). To determine the anti-tumor 
potential of immunization with FAP-treated DCs, 
mice were intraperitoneally injected 3 times (1 
week apart) with immature DCs and OVA (1 
μg/ml)-pulsed DCs (1 ×10
6) treated with or without 
FAP (500 ng/ml), followed by subcutaneous 
injection of EG7 thymoma cells (1 ×10
6) into the 
right lower back. Injection of DCs pulsed with 346    Exp. Mol. Med. Vol. 44(5), 340-349, 2012
Figure 5. FAP triggers DC-derived anti-tumor activity in vivo. (A) Mice 
were intraperitoneally injected 3 times (1 week apart) with immature DCs 
and OVA (1 μg/ml)-pulsed DCs (1 ×10
6) treated with or without FAP, 
followed by subcutaneous injection of EG7 thymoma cells (1 ×10
6) into 
the right lower back. The tumor size was measured every 4 days, and 
the tumor mass was calculated. n = 4 mice/group. *P ＜ 0.05. (B) 
Survival of mice was recorded for up to 100 days, n = 4 mice/group.
OVA257-264 significantly reduced the size of the 
OVA-expressing EG7 tumors compared to tumors 
in mice receiving DCs that have not been pulsed 
with OVA (Figure 5A). Interestingly, EG7 tumors in 
mice that received FAP-treated DCs pulsed with 
OVA were smaller than those in mice that received 
DCs pulsed with OVA (Figure 5A). Consistent with 
this, the group of mice injected with FAP-treated 
OVA-pulsed DCs showed a significant prolongation 
of survival compared to mice injected with 
OVA-pulsed DCs or DCs that have not been 
pulsed with OVA (Figure 5B). 
Discussion
Recently, studies on the regulation of the immune 
response by M. avium subsp. paratuberculosis 
have been reported (Lei et al., 2007; Lee et al., 
2009). It is well known that M. avium subsp. 
paratuberculosis is crucial for Johne’s disease in 
animals. In addition, on the basis of recent clinical 
trials, it is considered a possible cause of Crohn’s 
disease, an inflammatory disease of the intestines. 
Crohn’s disease is considered an autoimmune 
disease because the immune system attacks the 
gastrointestinal tract, causing chronic inflammation 
(Abraham and Cho, 2009). 
    DCs function as a crucial player in the innate 
and adaptive immune response. Thus, anti-tumor 
immune responses to DC-based vaccination have 
been suggested and studied with regard to the 
above-mentioned DC functions. In this study, we 
demonstrated following novel properties of the M. 
avium subsp. paratuberculosis FAP. 1) FAP-mediated 
DC maturation is via TLR4. 2) FAP-mediated DC 
maturation is via GSK-3. 3) FAP could be utilized 
for DC- based cancer vaccine as an immune- 
enhancement adjuvant.
    TLR4  agonists  have  a  broad  spectrum  of 
immunoregulatory applications, e.g., as adjuvants 
for vaccine treatment of chronic viral infections and 
in tumor therapy (Cisco et al., 2004). Although 
LPS, a representative agonist of TLR4, is 
appropriate for immune enhancement, it is not 
applicable for anti-tumor immunity due to the risk of 
endotoxemia. In a previous study, we had shown 
that FAP is less toxic to DCs in vitro (Lee et al., 
2009). Due to the non-toxic effects on DCs, we 
suggest that FAP is a potentially suitable adjuvant 
for immunotherapy.
    Although M. avium subsp. paratuberculosis is a 
dangerous pathogen threatening animals and 
humans, FAP is applicable for the enhancement of 
immunogenicity because of its immunostimulatory 
ability. Our study provides for the first time 
evidence that FAP is an efficient TLR4 agonist. 
Further research to elucidate the exact mechanism 
underlying the regulation of DCs by FAP is currently 
underway. A more precise understanding of the 
interrelationship between DCs and M. avium subsp. 
paratuberculosis will provide crucial information for 
the therapy of cancer.
Methods
Animals and reagents
We purchased 4- to 8-week-old male C57BL/6 mice from 
the Korean Institute of Chemistry Technology (Daejeon, 
Korea). C57BL/6 OT-1 T-cell receptor (TCR) transgenic 
mice, C57BL/6J TLR2
-/- (B6.129-Tlr2
tm1Kir/J), and C57BL/10 
TLR4
-/- (C57BL/10ScNJ) were purchased at 6-8 weeks of 
age from the Jackson Laboratory (Bar Harbor, ME). All 
mice were housed in a specific pathogen-free environment 
and used in accordance with the institutional guidelines for 
animal care. Recombinant murine granulocyte-macro-
phage colony-stimulating factor (rmGM-CSF) and rmIL-4 
were purchased from R&D Systems (Minneapolis, MN). 
Cytokine enzyme-linked immunosorbent assay (ELISA) 
kits for murine IL-12p70, tumor necrosis factor-alpha 
(TNF-α), and IL-10 were purchased from R&D Systems. 
Fluorescein isothiocyanate (FITC)- or phycoerythrin 
(PE)-conjugated monoclonal antibodies (mAbs) used to 
detect the expression of TLR4, CD11c (HL3), CD80 
(16-10A1), CD86 (GL1), I-A
b β-chain (AF-120.1), and H-2K
b 
(AF6-88.5) by flow cytometry, as well as isotype-matched 
control mAbs and the biotinylated anti-CD11c (N418) mAb 
were purchased from R&D Systems. Alexa568-conjugated 
rabbit IgG Ab and anti-mouse TLR4/MD-2 complex Ab 
were purchased from eBioscience, Inc. (San Diego, CA). 
Anti-phospho-ERK, anti-ERK, anti-phospho-p38, anti-phos-
pho-JNK, and anti-I-κB Abs were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).M. avium subsp. paratuberculosis FAP for cancer vaccines    347
Cell lines
The cell lines EL4, a thymoma-derived cell line, and EG7, 
an OVA-expressing EL4 variant were purchased from the 
American Type Culture Collection (ATCC; Manassas, VA) 
and cultured in RPMI 1640 supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 100 U/ml pen-
icillin, 100 μg/ml streptomycin, and 10 mM L-glutamine (all 
purchased from Invitrogen, Carlsbad, CA) at 37
oC in a 5% 
CO2 atmosphere. 
Expression and purification of recombinant FAP
Preparation of recombinant FAP has been described 
previously (Cho et al., 2007). Briefly, genomic DNA was 
isolated from the M. avium subsp. paratuberculosis 
JTC303 strain, and the DNA encoding FAP (MAP1569) 
was amplified by PCR. After purification of the PCR 
product, it was ligated into the pET-22b(+) vector digested 
with the NdeI and XhoI enzymes. Expression of FAP in 
transformed BL21(DE3) cells was induced with isopropyl- 
beta-D-thiogalactopyranoside (IPTG) (Promega, Madison, 
WI). The soluble FAP was extracted after cell disruption by 
sonication. FAP containing a C-terminal histidine tag was 
purified using Ni-nitrilotriacetic acid (NTA) resin (Qiagen, 
Chatsworth, CA). The FAP was dialyzed five times in 10 
mM phosphate-buffered saline (PBS) (pH 7.2) using a 
Slide-A-Lyzer dialysis cassette with a 3-kDa cutoff (Pierce, 
Rockford, IL). After dialysis, contaminating endotoxin was 
removed using Detoxi-Gel Affinity Pak columns (Pierce, 
Rockford, IL). FAP was incubated with endotoxin removal 
resin overnight to remove LPS and concentrated with a 
Centricon device (2,000-Da cutoff; Millipore). Also, 
endotoxin was assayed under endotoxin-free experimental 
conditions using a Limulus amebocyte lysate pyrogen kit 
(Biowhittaker, Walkersville, MD). The experiments were 
conducted according to the manufacturer's protocol. The 
quantity of endotoxin in the FAP was ≤0.01 ng/mg. The 
final concentration of purified FAP was determined using a 
bicinchoninic acid protein assay kit (Pierce, Rockford, IL).
Generation and culture of DCs
Primary culture of DCs was performed as previously de-
scribed (Jung et al., 2010), with slight modification. Briefly, 
bone marrow (BM) was flushed from the tibiae and femurs 
of 6 to 8-week-old male C57BL/6 mice and depleted of red 
blood cells (RBCs) using a red blood cell lysing buffer 
(Sigma-Aldrich, St. Louis, MO). The cells were then plated 
in 6-well culture plates (1 ×10
6 cells/ml; 2 ml per well) in 
RPMI 1640 supplemented with 10% heat-inactivated FBS, 
100 U/ml penicillin, 100 mg/ml streptomycin, 20 ng/ml 
rmGM-CSF, and 10 ng/ml rmIL-4 at 37
oC in 5% CO2. On 
days 3 and 5, the floating cells were gently removed from 
the cultures and fresh medium was added. On day 6 of the 
culture, non-adherent cells and loosely adherent proliferat-
ing DC aggregates were harvested and re-plated in 60-mm 
dishes (1 ×10
6 cells/ml; 5 ml/dish) for stimulation and 
analysis. On day 7, 80% or more of the non-adherent cells 
expressed CD11c. In certain experiments, the DCs were 
labeled with bead-conjugated anti-CD11c mAb (Miltenyi 
Biotec, Gladbach, Germany) and then subjected to positive 
selection through paramagnetic columns (LS columns; 
Miltenyi Biotec), according to the manufacturer’s in-
structions, to obtain highly-purified populations for sub-
sequent analysis. The purity of the selected cell fraction 
was ＞90%.
Flow cytometric analysis
On day 7, the BMDCs were harvested, washed with phos-
phate buffered saline (PBS), and resuspended in FACS 
washing buffer (2% FBS and 0.1% sodium azide in PBS). 
The cells were first blocked with 10% (v/v) normal goat se-
rum for 15 min at 4
oC and then stained with PE-conjugated 
anti-H-2K
b, anti-I-A
b, anti-CD80, anti-CD86, anti-MHC class 
I, anti-MHC class II, or with FITC-conjugated anti-CD11c 
for 30 min at 4
oC. Finally, the stained cells were analyzed 
using the FACSCalibur flow cytometer (Becton Dickinson, 
San Jose, CA).
Mixed leukocyte reaction
Transgenic OVA-specific CD8
+ T-cells were purified from 
bulk splenocytes via negative selection by using a mouse 
CD8
+ T-cell kit (Miltenyi Biotec). The purity of the obtained 
cell population was assessed to be ＞93% by flow cy-
tometry after staining with a Cy5-conjugated anti-CD8 Ab. 
Briefly, the cells were resuspended in 5 μM carboxy-
fluorscein diacetate succinimidyl ester (CFSE) in DMSO 
and shaken for 10 min at room temperature. Next, the cells 
were washed once in pure FBS and twice in PBS with 10% 
FBS. DCs (1 ×10
5) were then exposed to FAP for 24 h 
and subsequently co-cultured with 1 ×10
6 CFSE-labeled T 
lymphocytes in 96-well, U-bottom plates. After 3 days, the 
cells were harvested, stained with a Cy5-labeled anti-CD8 
monoclonal Ab (to gate OT-1 T-cells), and then assessed 
by flow cytometry.
In vitro cytotoxicity assays
To determine the effect of FAP on the induction of 
OVA-specific CTLs, cytotoxicity assays were performed. In 
mixed cultures, immature DCs, OVA-pulsed DCs, or 
OVA-pulsed FAP-treated DCs were first cultured with sple-
nocytes of OT-1 TCR transgenic mice (1 ×10
6 per well) for 
72 h and then co-cultured with EL4 (1 ×10
6, cells stained 
with 1 μM CFSE) or EG7 cells (1 ×10
6 cells stained with 
10 μM CFSE). After 4 h, the mixed lymphocyte tumor cul-
tures were analyzed by flow cytometry.
Cytokine assay
Murine IL-12p70, TNF-α, and IL-10 were measured using 
an ELISA kit according to the manufacturer’s instructions.
Confocal laser scanning microscopy
The cells were permeabilized with 1% saponin for 3 min, 
stained with rabbit anti-FAP and rat anti-TLR4/MD2 Abs 
overnight at 4
oC, and then stained with rabbit anti-FAP and 
mouse PE-conjugated anti-TLR4 antibodies overnight at 
4
oC, and then stained with Alexa568-conjugated anti-rabbit 
antibody for 1 h at room temperature. Cell morphology and 348    Exp. Mol. Med. Vol. 44(5), 340-349, 2012
fluorescence intensity were analyzed using the Zeiss 
LSM510 Meta confocal laser scanning microscope (Zeiss, 
Jena, Germany). Images were acquired using the LSM510 
Meta software and processed using the LSM image 
examiner.
Co-immunoprecipitation analysis
Co-immunoprecipitation analysis was performed as pre-
viously described (Noh et al., 2010), with slight 
modification. The cells were lysed in lysis buffer (0.5% 
NP-40, 1 mM EDTA, 50 mM Tris-HCl, pH 8.0, 120 mM 
NaCl), and the lysates were subjected to 10 min of micro-
centrifugation at 12,000 g. The supernatant was then in-
cubated for 2 h at 4
oC with the anti-FAP Ab, after which the 
mixture was incubated for an additional 1 h at 4
oC with pro-
tein G-coupled sepharose beads (Amersham Pharmacia 
Biotech, Uppsala, Sweden). The resultant precipitates 
were subjected to SDS-PAGE and immunoblotted with an-
ti-TLR4 Ab. 
Immunoblot analysis
In brief, cell lysates were subjected to SDS-PAGE and 
transferred to PVDF membranes. The PVDF membranes 
were then blocked with 5% nonfat milk in a washing buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) 
and incubated with the indicated antibodies for 1 h at room 
temperature. The membranes were washed and incubated 
for 1 h at room temperature with the appropriate secondary 
antibodies conjugated with horseradish peroxidase 
(Amersham Pharmacia Biotech, Uppsala). Protein bands 
were visualized using an enhanced chemiluminescence 
system (Amersham Pharmacia Biotech, Uppsala).
Statistical analysis
All experiments were repeated at least 3 times with con-
sistent results. Unless otherwise stated, data are ex-
pressed as the mean ± SEM. Analysis of variance was 
used to compare experimental groups with control values, 
while comparisons between multiple groups were made 
using Tukey’s multiple comparison tests (Prism 3.0 
GraphPad software). A P value less than 0.05 was consid-
ered to indicate statistical significance.
Supplemental data
Supplemental Data include two figures and can be found 
with this article online at http://e-emm.or.kr/article/article_ 
files/ SP-44-5-04.pdf.
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